RE: Molnupiravir EUA
Here we go...
Molnupiravir has been EUA’d for “mild-to-moderate” cases of “Covid-19” for individuals considered at risk of severe disease, despite FDA panel ambivalence during the November 30 review owing to the poor efficacy findings in the second portion of the trial, bone marrow toxicity signals, and failure to pass one of two carcinogenicity assays.1
New subscribers interested in the staggering potential toxicity of the drug for recipients and for the environment at large will find my previous review here:
See https://www.fda.gov/media/154418/download
“Significant bone marrow toxicity was reported in a 28-day toxicology study in dogs.”
“The results of the Pig-a assay were “equivocal” as the assay showed a positive trend but results did not exceed the range of negative historical control values.”
This may or may not be related to the statement in the EUA (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain):
“Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth.”
FDA are handing out EUAs like they're candy. wtaf? FDA rhymes with, "pay to play" though, so there's that.
Once you make a bunch of some 'drug', regardless of whether it works or not, it is almost impossible to dispose of it. Antibiotics, for instance, keep doing their damage no matter if they exit your body, or are dumped on the ground. They keep killing their target forever. When I hear about any new drug, this is what I think first; was it just some poison that was too expensive or impossible to dump so the drug companies simply present it as a new drug. A few sham drug trials and boom, you are making money again with the same poison that killed the previous folks.
We gotta stop makin' most of this stuff in the first place it seems.